Canada Markets close in 5 hrs 1 min

Nabriva Therapeutics plc (NBRV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4975-0.0125 (-2.45%)
As of 10:58AM EDT. Market open.

Nabriva Therapeutics plc

25-28 North Wall Quay
Dublin 1
353 1 649 2000

Full Time Employees162

Key Executives

NameTitlePayExercisedYear Born
Mr. Theodore R. SchroederCEO & Director707.62kN/A1955
Dr. Steven P. GelonePres & COO667.5kN/A1968
Dr. Colin BroomDirector39.13kN/A1956
Dr. Jennifer Schranz M.D.Chief Medical Officer620.85kN/A1965
Mr. Gary L. SenderChief Financial OfficerN/AN/A1962
Mr. Robert L. CrottyGen. Counsel & Sec.N/AN/A1974
Mr. Francesco Maria LavinoChief Commercial OfficerN/AN/A1973
Mr. Werner HeilmayerVP of CMC & IPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; for the treatment of acute bacterial skin and skin structure infection; and that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, osteomyelitis, and prosthetic joint infections. It is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Nabriva Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.